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ABSTRACT A recently cloned isoform of cGMP-
dependent protein kinase (cGK), designated type II, was
implicated as the mediator of cGMP-provoked intestinal Cl2
secretion based on its localization in the apical membrane of
enterocytes and on its capacity to activate cystic fibrosis
transmembrane conductance regulator (CFTR) Cl2 channels.
In contrast, the soluble type I cGK was unable to activate
CFTR in intact cells, although both cGK I and cGK II could
phosphorylate CFTR in vitro. To investigate the molecular
basis for the cGK II isotype specificity of CFTR channel
gating, we expressed cGK II or cGK I mutants possessing
different membrane binding properties by using adenoviral
vectors in a CFTR-transfected intestinal cell line, and we
examined the ability of cGMP to phosphorylate and activate
the Cl2 channel. Mutation of the cGK II N-terminal myris-
toylation site (Gly23 Ala) reduced cGK II membrane binding
and severely impaired cGK II activation of CFTR. Conversely,
a chimeric protein, in which the N-terminal membrane-
anchoring domain of cGK II was fused to the N terminus of
cGK Ib, acquired the ability to associate with the membrane
and activate the CFTR Cl2 channel. The potency order of cGK
constructs for activation of CFTR (cGK II > membrane-
bound cGK I chimer >> nonmyristoylated cGK II > cGK Ib)
correlated with the extent of 32P incorporation into CFTR
observed in parallel measurements. These results strongly
support the concept that membrane targeting of cGK is a
major determinant of CFTR Cl2 channel activation in intact
cells.
The cystic fibrosis transmembrane conductance regulator
(CFTR) Cl2 channel plays an important role as a mediator of
salt and fluid transport across numerous epithelial tissues (1).
The absence of functional CFTR Cl2 channels in the plasma
membrane of epithelial cells either from patients with the
genetic disease cystic fibrosis or from CFTR knockout mice
causes severe disturbances in the salt and water content of
luminal f luids, leading to potentially lethal lung infections
andyor pancreas and intestinal obstructions (meconium ileus)
(1, 2). In contrast, the hyperactivation of CFTR Cl2 channels
in intestinal epithelium by several enterotoxins causes a mas-
sive secretory diarrhea that is responsible for a large part of the
infant death in developing countries (3). Therefore, the activity
of CFTR must be regulated strictly under physiological con-
ditions (1, 3). In most epithelia, phosphorylation of the regu-
latory domain of CFTR by cAMP-dependent protein kinase
(cAK), possibly in combination with protein kinase C (4), is
believed to be the primary activating step, followed by ATP-
bindingyhydrolysis at the nucleotide binding domains (1).
However, in intestinal epithelium, a recently cloned isotype of
cGMP-dependent protein kinase, cGK type II has been im-
plicated as an additional regulator of CFTR (3, 5–8). This
pathway for CFTR activation functions independently from
that of cAK (8) and is triggered by membrane-permeant cGMP
analogs and presumably by guanylin, an endogenous cGMP-
elevating peptide hormone (3, 6, 7). Furthermore, pharmaco-
logical (9) and gene disruption techniques (10) recently have
demonstrated that cGK II is involved critically in the secretory
diarrhea caused by heat-stable enterotoxins, which, like gua-
nylin, are known activators of guanylyl cyclase C in intestinal
epithelial cells (3, 11).
Type II cGK is a membrane-bound enzyme that is related
closely to the soluble type I cGK (consisting of a and b
isoforms) (5, 7). Both isotypes have been shown to phosphor-
ylate a number of substrates in vitro with similar kinetics (3, 7,
12, 13), including CFTR and a peptide comprising the regu-
latory domain of CFTR (CF-2; ref. 8). However, only cGK II,
not cGK I, was able to phosphorylate and activate CFTR in
membrane patches or whole cells (8, 14), suggesting that the
subcellular localization of cGKs, clearly different for types II
and I (7, 14), might determine the efficacy of cGK interaction
with CFTR under physiological conditions. To investigate this
possibility, we expressed cGK II or cGK I mutants possessing
different membrane-binding properties in a CFTR-transfected
intestinal cell line (IEC-CF7) and examined the ability of
cGMP to phosphorylate and activate the CFTR Cl2 channel.
Here, we report that cGK membrane association is a strong
determinant of the potency of cGK forms for activating CFTR
Cl2 channels in intact cells.
EXPERIMENTAL PROCEDURES
Materials. Protein A Sepharose was obtained from Phar-
macia; 3-isobutyl-1-methyl-xanthine and rat atrial natriuretic
peptide (ANP) were obtained from Sigma; cGMP analogs
were obtained from BioLog Life Science Institute (Bremen,
Germany), and [32P]orthophosphate, [g-32P]ATP, 125I2, and
the enhanced chemiluminescence system were obtained from
Amersham. Polyclonal cGK II or cGK I antibodies, raised
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against recombinant cGK II or cGK Ib expressed in Esche-
richia coli, were prepared as described (6). The polyclonal
antibody C449 against CFTR (15) and CF-2, a cloned regu-
latory domain of CFTR (15), were gifts from A. C. Nairn
(Rockefeller University, New York). The cGK substrate pep-
tide 2A3 (RRKVSKQE) and the Walsh inhibitor peptide [PKI
(5–24) amide] were synthesized by D. Palm (University of
Wu¨rzburg, Wu¨rzburg, Germany).
Construction of cGK Mutants and Adenovirus (Ad) Vec-
tors. A nonmyristoylated mutant of cGK II (G2A) was con-
structed by mutation of Gly2 to Ala as described (16). A cGK
chimer containing the N-terminal sequence of cGK II fused to
the N terminus from cGK Ib was made subsequent to using the
Transformer site-directed mutagenesis kit (CLONTECH) to
introduce a unique NheI restriction site in the N terminus of
human cGK Ib (17) just upstream of Leu7, changing Arg5–Asp6
to Leu–Ala. The sequence coding for the first 29 N-terminal
amino acids of cGK II was obtained by PCR amplification of
a 0.8-kb fragment (beginning at a MluI site in pRcyCMV–cGK
II (5) and ending at a new NheI site attached downstream of
the codon for Lys29] and was ligated into the mutated cGK Ib
in a pRcyCMV vector. Recombinant replication-deficient (E1
deletion) Ad type 5 containing the coding sequences of rat
cGK II (5) or human cGK Ib (17) were prepared as described
(14). The coding sequence of the cGK II-G2A mutant, or of
the cGK II-cGK Ib chimer (cGK chimer), was introduced into
the adenoviral vectors similarly as described for cGK II (14).
The titer of the adenoviral preparations was '1 plaque
forming unity500 particles.
Culture and Infection of IEC-CF7 Cells. Rat intestine-
derived IEC-6 cells stably expressing CFTR (IEC-CF7; ref. 18)
were cultured in DMEM supplemented with 5% fetal calf
serum, 0.1 unityml insulin, 0.2 mgyml G418, 0.1 mgyml
streptomycin, and 0.04 mgyml penicillin. Two days after
plating, confluent monolayers of cells were infected by adding
medium containing the adenoviral vectors (usually 5 3 109
particlesyml).
Determination of Subcellular Localization of cGK Con-
structs by Immunofluorescence Confocal Microscopy. IEC-
CF7 cell were grown on glass coverslips in 12-well plates. Two
days after infection, cells were fixed with 3% paraformalde-
hyde and subsequently with 100% methanol. After incubation
with cGK I- or II-specific antisera (1:100) and an fluorescein
isothiocyanate-coupled secondary antibody, cells were embed-
ded in antifading medium consisting of 0.9 M 1,4-
diazabicyclo[2.2.2] octane in 60% glycerol, and immunofluo-
rescence was detected by using a Zeiss confocal laser micro-
scope LSM 410. A 488-nm argon laser was used for excitation,
and emission was detected by using a 515- to 540-bandpass
filter.
Protein Kinase Assays and Immunoblotting. Two days after
infection, cells were suspended in buffer A (150 mM NaCly10
mM sodium phosphate, pH 7.4y1 mM EDTA) and homoge-
nized by brief sonication. Cytosol and membranes were sep-
arated by centrifugation at 150,000 3 g for 60 min at 4°C in a
Beckman airfuge. Protein kinase activity was determined in 40
ml of 20 mM TriszHCl (pH 7.4), 10 mm MgCl2, 10 mM
b-mercaptoethanol, 200 nM of the cAK inhibitor peptide [PKI
(5–24) amide], 0.1 mM 3-isobutyl-1-methyl-xanthine, 25 mM
b-glycerophosphate, 0.1 mgyml cGK substrate peptide 2A3, 1
mCi of g [32P]ATP, 300 mM nonlabeled ATP, and various
concentrations of cGMP as described (16). For the measure-
ments of phosphorylation of the cloned regulatory domain of
CFTR (CF-2; ref. 15), cGK was extracted from the adenoviral
vector-infected IEC-CF7 cells with 0.5 M NaCl and 1% Triton
X-100 and purified by affinity chromatography on 8-(2-
aminoethyl) amino-cAMP Sepharose (8). CF-2 (0.1 mM) was
phosphorylated by incubation with purified cGK bound to the
affinity gel in the buffer used for 2A3 phosphorylation, except
for the presence of 50 mM ATP and 15 mM cGMP. Subse-
quently, CF-2 was separated on 12.5% SDSyPAGE, and the
32P incorporated was quantitated by the Bio-Rad Molecular
Imaging System GS-363. Expression of cGK constructs was
determined by immunoblotting and was quantitated by a
PhosphoImager (Molecular Dynamics) as described (14). Spe-
cific activities of the cGK constructs were calculated by
dividing the cGMP-stimulated phosphotransferase activities
by the amount of cGK protein in the corresponding homog-
enates.
125I2 Efflux Studies. Confluent IEC-CF7 cells grown in
12-well plates and infected 2 days earlier were loaded with
tracer 125I2 (5 mCiyml) for 1.5 h (19). After removal of the
extracellular isotope, fractional 125I2 efflux was determined at
37°C by the addition and consecutive replacement of the
extracellular medium at 1- to 3-min intervals as described (14,
19).
Phosphate Labeling and Immunoprecipitation of CFTR.
Two days after infection, confluent cells grown in 6-well plates
(Costar) were incubated at 37°C for 1 h in phosphate-free,
modified Meyler solution supplemented with 0.5 mCiyml
[32P]orthophosphate (14). Labeled cells were incubated for an
additional 20 min with membrane-permeable cGMP analogs in
the same medium. 32P-labeled CFTR was immunoprecipitated
with affinity, purified anti-CFTR antibody C449 as described
(14, 15), separated by 6% SDSyPAGE, visualized by autora-
diography, and quantitated with the Molecular Imaging Sys-
tem GS-363 (Bio-Rad).
RESULTS
Expression of cGK Mutants with Different Membrane
Binding Properties. The membrane binding of cGK II was
shown to be critically dependent on the presence of a myristoyl
group at the cGK II N terminus and could be disrupted by
mutating the Gly at position 2 to an Ala (G2A; ref. 16).
Conversely, we postulated that it could be possible to target the
soluble cGK Ib to the membrane by attaching the first 29
amino acids of cGK II, containing the myristoylation signal
plus a polybasic domain (16), to the cGK Ib N terminus. This
cGK chimer as well as the G2A mutant were cloned into
adenoviral (Ad) vectors like those used previously for wild-
type cGK constructs for efficient expression in the CFTR-
transfected intestinal cell line IEC-CF7, which contains very
little endogenous soluble cGK and no detectable cGK II (14).
Infection of IEC-CF7 cells with the recombinant viral vectors
(5 3 109 particlesyml) resulted in a relatively high level of
expression of G2A, cGK chimer, and cGK Ib (1.7 6 0.3, 2.3 6
0.5, and 2.4 6 0.6 mgymg protein, respectively, as assessed by
immunoblotting; n 5 3; data not shown), whereas cGK II was
expressed at a 3- to 4-fold lower level (0.6 6 0.2 mgymg protein;
n 5 3). The various cGK constructs exhibited: (i) similar Kas
for cGMP (0.6–0.8 mM; data not shown) and (ii) similar
specific activities for phosphorylating the cGK-specific peptide
2A3 (0.5–1 mmol of phosphate incorporated per minute per
milligram enzyme protein; data not shown. cf. Fig. 1 and ref.
14 for cGK Ib). Furthermore, the cGK constructs, purified
from infected IEC-CF7 cells (see Materials and Methods),
phosphorylated the recombinant regulatory domain of CFTR
(CF-2) with similar specific activities in vitro (1.0–1.8 arbitrary
unitsyminymg protein; data not shown; cf. ref. 8).
The cGK mutants expressed differed in their subcellular
localizations. Whereas cGK II was recovered mainly in the
particulate fraction, a major part of the kinase activity asso-
ciated with the myristoylation-deficient cGK II mutant (G2A)
was recovered in the cytosolic fraction (Fig. 1), although a
portion of the G2A mutant did remain associated with the
particulate fraction. Expressed cGK Ib was almost completely
cytosolic (14). In contrast, the cGK chimer, containing the
cGK II myristoylation sequence, was targeted predominantly
to the membrane, similar to cGK II. Immunofluorescence
confocal microscopy confirmed the cytosolic localization of
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cGK Ib and G2A and the presence of cGK II and the cGK
chimer in the plasma membrane (Fig. 2). Additional localiza-
tion of the cGK chimer in intracellular compartments was also
evident. Furthermore, highly efficient expression of the vari-
ous cGK constructs was detected in most IEC-CF7 cells,
although a small percentage (5–10%) of cells contained con-
siderably more cGK immunoreactivity than the average (Fig.
2). The efficient expression of active cGK mutants in IEC-CF7
cells displaying different membrane binding properties pro-
vided a basis for the meaningful comparison of the effects of
these mutants on CFTR Cl2 channel activity and CFTR
phosphorylation.
Activation of CFTR by cGK Mutants. Activation of CFTR
in IEC-CF7 cells can be measured accurately and sensitively by
monitoring the 125I2 efflux from these cells (14). We have
shown previously that membrane-permeable cGMP analogs,
or the cGMP-elevating hormone ANP, failed to provoke
CFTR-channel opening in mock-infected IEC-CF7 cells (14).
In agreement with this previous study, cGK II but not cGK Ib
expression rendered CFTR susceptible to activation by cGMP
(Fig. 3B). However, abolishment of the N-terminal myristoyl-
ation of cGK II by the G2A mutation strongly impaired the
ability of cGK II to stimulate CFTR-mediated 125I2 efflux,
although some small residual activity remained (Figs. 3 and 4).
Conversely, the fusion of the N-terminal myristoylation se-
quence of cGK II to cGK Ib produced a cGK chimer capable
of stimulating 125I2 efflux in response to cGMP or ANP. The
activation of CFTR by this cGK I chimer permitted the
comparison of the cGMP analog sensitivity of cGK II and Ib
within the same cell type. b-Phenyl-1,N2-etheno-8-bromo-
cGMP (8-Br-PET-cGMP), defined as a cGK I selective ago-
nist, (20 mM; refs. 20 and 21), provoked a clear increase in 125I2
efflux in cGK chimer expressing IEC-CF7 cells but not in cGK
II containing cells (Fig. 3B). Conversely, the cGK II-selective
agonist 8-(4-chlorophenylthio)-cGMP (50 mM; ref. 21) was a
potent activator of CFTR in cGK II-expressing cells but
provoked only one-half of the 8-Br-PET-cGMP-induced in-
crease in 125I2 efflux in cGK chimer expressing cells (Fig. 3B).
To determine the relative potencies of the various cGK
mutants in activating CFTR, the effect of different cGK II
expression levels was measured on the initial ANP-induced
increase in 125I2 efflux. At a physiologically relevant expres-
sion level of '0.6 mg of cGK II per milligram protein (for
comparison rat enterocytes contain 0.2–0.4 mg of cGK II per
milligram protein; ref. 14), we estimated that cGK II is '3-fold
more potent than the cGK chimer, and 30-fold more potent
than G2A (Fig. 4). cGK Ib was clearly the least potent activator
of CFTR because its expression at an even fourfold higher
level (2.4 mgymg protein) did not lead to any measurable
stimulation of 125I2 efflux in response to ANP (Figs. 3B and 4).
Phosphorylation of CFTR by cGK Mutants. To investigate
the molecular mechanism of CFTR activation by the cGK
mutants, we determined their effect on the in situ phosphor-
ylation of CFTR. As shown in Fig. 5, membrane-permeable
cGMP analogs increased 32P incorporation into CFTR in cells
expressing cGK II, cGK chimer, or G2A. However, the level of
cGMP-stimulated CFTR phosphorylation was higher in cGK
II-expressing cells than in cells expressing cGK chimer and
much higher than in cells expressing the myristoylation mutant
G2A. Furthermore, the basal level of CFTR phosphorylation
was higher in cells expressing cGK II than in cells expressing
the other cGK constructs (Fig. 5).
DISCUSSION
Our results indicated that the membrane localization of cGK
II was an important determinant of the capacity of cGK II to
FIG. 1. Adenoviral vector expression of cGK constructs in IEC-
CF7 cells. Rat intestinal IEC-CF7 cells were infected with 5 3 109
particlesyml ('107 plaque forming unitsyml) of replication-deficient
adenoviral vectors containing the cDNA of either cGK II, a myris-
toylation-deficient cGK II mutant (G2A), or the N terminus of cGK
II fused to the N terminus of cGK Ib (chimer). Two days after
infection, cells were harvested, homogenized (open bar), and sepa-
rated into cytosolic (filled bar) and membrane (150,000 3 g, hatched
bar) fractions. Phosphotransferase activity (nmolymin) was deter-
mined in the presence or absence of 10 mM cGMP and was expressed
per milligram of homogenate protein after correction for basal activity
in the absence of cGMP. Shown are means 6 SD of three experiments.
(Inset) Immunoblots of the homogenate (H; 10 mg protein), cytosol
(S), and membrane (P) fractions from cells infected with adenoviral
vectors containing the cGK constructs described above and labeled
with cGK I- or cGK II-specific antibody.
FIG. 2. Subcellular localization of cGK proteins expressed in
IEC-CF7 cells. (A) Rat intestinal IEC-CF7 cells were infected with
replication-deficient Ad (5 3 109 particlesyml) containing the cDNA
of either cGK Ib. (B) The N terminus of cGK II fused to the N
terminus of cGK Ib. (C) cGK II. (D) G2A, a myristoylation-deficient
cGK II mutant. Two days after infection, localization of the expressed
cGK proteins was determined by using immunofluorescence confocal
microscopy. Specificity of the cGK staining was confirmed by the
absence of signal in mock-infected IEC-CF7 cells (not shown).
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activate CFTR. Mutation (G2A) of the cGK II myristoylation
site impaired the membrane-anchoring of cGK II and reduced
cGK II activation of CFTR by 30-fold, although cGMP acti-
vation of the mutated cGK II remained unchanged. A rela-
tively small residual activation of CFTR by ANP, observed in
G2A expressing IEC-CF7 cells, may derive from the G2A
(30–40% of the G2A kinase activity) still associated with the
particulate fraction of these cells. This fraction of particulate
G2A was considerably greater than that observed previously in
experiments with the same construct in COS-1 cells (10–20%,
ref. 16). There appears to be some difference in the membrane
association of cGK II in these two cell types, which may depend
on the extent of cytoskeletal participation in cGK II anchoring.
The solubilization of wild-type cGK II from IEC-CF7 cells
with Triton X-100 required addition of 0.5 M NaCl in IEC-CF7
cells but not in COS-1 cells (cf. ref. 16; A.B.V., unpublished
observations). A cytoskeletal association of the residual par-
ticulate pool of G2A in IEC-CF7 cells in the present study also
may explain why particulate G2A was not detected in the
plasma membrane by confocal microscopy.
Furthermore, this study also indicates that the failure of
soluble cGK Ib to activate CFTR in whole cells predominantly
results from the lack of cGK Ib membraneysubstrate targeting.
Notably, this study and previous studies (8) demonstrated no
lack of intrinsic recognition of CFTR as a substrate by cGK I
because CFTR or its regulatory domain, CF-2, was a good
substrate for cGK I in vitro. Now, fusion of amino acids 1–29
of cGK II to the N terminus of cGK I produced a chimer
capable of opening CFTR Cl2 channels, showing that the
N-terminal membrane-anchoring piece of cGK II dramatically
improved CFTR activation by the type I isozyme. Although the
gain of function observed with the cGK IyII chimer is most
likely due to the acquisition of a myristoyl anchor, additional
cGK II-specific targeting motifs may be present in the N
terminus or in other regions of cGK II. The latter possibility
may explain why the chimer was 60–70% less effective than
cGK II as an activator of CFTR in the IEC-CF7 cell model.
Although the chimer was found rather exclusively in the pellet
fraction (after 150,000 3 g centrifugation), this fraction con-
tains a heterogeneous mixture of different membranes, and
without possible additional regions of cGK II for appropriate
membrane attachment, some chimer may be located in intra-
cellular membranes not containing CFTR (cf. Fig. 2). Mem-
brane attachment also may cause certain conformational
changes in cGK II that cannot be mimicked completely by cGK
I. In any case, there was a clear correlation between myris-
toylation and activation of CFTR, i.e., cGK II . chimer .
G2A . cGK Ib. The same rank order of these constructs was
observed for phosphorylation of CFTR, indicating that CFTR
phosphorylation also was dependent on the membrane asso-
ciation of cGK and that phosphorylation was the key step in
CFTR activation by cGK.
The dependence of CFTR activation in intact cells on cGK
subcellular localization supports the emerging concept that
compartmentalization of protein kinases and their substrates
is a major determinant of their interaction under physiological
conditions (22). Targeting of a kinase to its substrate may
involve kinase lipidation, as exemplified by cGK II and the
tyrosine kinases of the Src family (23), or may require specific
anchoring to scaffolding proteins, as shown for some cAKs
(24). Modulation of the a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acidykainate channel and the L-type Ca21
channel by cAK was shown to require cAK binding to specific
anchoring proteins (25, 26). Of interest, preliminary studies
FIG. 3. Iodide efflux in IEC-CF7 cells expressing cGK constructs with different membrane binding properties. Rat intestinal IEC-CF7 cells
stably transfected with CFTR Cl2 channels were infected with replication-deficient Ad (5 3 109 particlesyml) containing the cDNA of either cGK
II, a myristoylation-deficient cGK II mutant (G2A), the N terminus of cGK II fused to the N terminus of cGK Ib (chimer), or wild-type cGK Ib.
Two days after infection, CFTR activity was monitored by using measurements of fractional 125I2 efflux. (A) Time course of 125I2 efflux. At 5
min (arrow), either 0.1 mM ANP (closed symbols) or vehicle (open symbols) was added to cells expressing cGK II (F, E), cGK chimer (, ), or
G2A (n, h). (B) Maximal increment in 125I2 efflux determined at 2 min after addition of forskolin and ANP in the case of cGK II, at 4 min in
the case of other constructs, and at 7 min after addition of cGMP analogs to IEC-CF7 cells infected as indicated. 125I2 efflux was corrected for
basal eff lux in the absence of the agonists at the same time points. Concentration of agonists used: 8-(4-chlorophenylthio)-cGMP, 50 mM (filled
bars); 8-Br-PET-cGMP, 20 mM (hatched bars); ANP, 0.1 mM (crosshatched bars); and forskolin, 10 mM (forsk; open bars). Data are means 6 SD
of three to four experiments.
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suggest a similar requirement for membrane anchoring of cAK
for CFTR activation. Type II cAK, which associates with
membrane anchor proteins (26), and not the unanchored type
I cAK, was identified as the cAK isozyme responsible for
cAMP-provoked CFTR activation in whole cells (27). The
importance of the subcellular localization of cGK I for inter-
action with certain substrates like vimentin (28, 29) and the
importance of nuclear translocation of cGK I for gene regu-
lation (30) also has been described.
One potential problem that could complicate approaches
using expression of recombinant enzymes to study physiolog-
ical effects of cGK (or other kinases) is that certain cells may
lack the appropriate substrates or anchor proteins. For exam-
ple, the regulation of the L-type Ca21 channel by the catalytic
subunit of cAK shown in cardiac myocytes could not be
demonstrated always in transfection systems (cf. refs. 26 and
31). So far, the cytoskeletal protein vimentin is the only specific
anchoring protein that has been described for cGK I (29).
Design of cGK I constructs that would be targeted to mem-
brane-bound substrates such as phospholamban and the IP3-
receptor (28) may prove useful for further investigating the
relationship between subcellular localization and function in
intact cells.
The observed advantage of cGK and CFTR colocalization
for their interaction raises the consideration that cGK II may
interact less efficiently with cytosolic substrates. It is therefore
tempting to speculate that other cGK II substrates yet to be
defined in brain (32, 33), kidney (34), and bone (10) may turn
out to be membrane proteins. Identification of physiological
cGK II substrates in addition to CFTR constitutes a major
challenge for the future.
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FIG. 4. Iodide efflux in IEC-CF7 cells expressing various levels of
cGK constructs. Rat intestinal IEC-CF7 cells stably transfected with
CFTR Cl2 channels were infected with different doses of replication-
deficient Ad containing the cDNA of either cGK II (F), a myristoy-
lation-deficient cGK II mutant (G2A, m), the N terminus of cGK II
fused to the N terminus of cGK Ib (chimer, ), or cGK Ib (E). The
doses of Ad used were: 1 and 5 3 109 particlesyml in the case of cGK
II; 0.25, 1, and 4 3 109 particlesyml in the case of G2A and chimer;
and 5 3 109 particlesyml in the case of cGK Ib. Two days after
infection, the initial cGK-mediated increase in CFTR activity was
monitored by measurement of the increment in fractional 125I2 efflux
2 min after addition of 0.1 mM ANP. The average level of cGK
expression obtained for each dose of virus was determined by immu-
noblotting and was plotted against the mean 6 SD of the correspond-
ing increase in 125I2 efflux (n 5 3).
FIG. 5. Phosphorylation of CFTR in IEC-CF7 cells expressing
cGK constructs. Rat intestinal IEC-CF7 cells, stably transfected with
CFTR Cl2 channels, were infected with replication-deficient Ad (5 3
109 particlesyml) containing the cDNA of either cGK II, a myristoy-
lation-deficient cGK II mutant (G2A), or the N terminus of cGK II
fused to the N terminus of cGK Ib (chimer). Two days after infection,
cells were labeled metabolically with inorganic 32P for 1 h and
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